Lexicon Pharmaceuticals | LXRX - Net Income


Lexicon Pharmaceuticals reported $-15.53M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Abbott USD 928M 149M Jun/2026
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
BioMarin Pharmaceutical USD 44.76M 60.76M Jun/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Eli Lilly USD 7.1B 301M Jun/2026
Halozyme Therapeutics USD 229.91M 79.86M Jun/2026
Illumina USD 207M 73M Jun/2026
Insmed USD -13.24M 150.32M Jun/2026
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
J&J USD 5.53B 299M Jun/2026
Lexicon Pharmaceuticals USD -15.53M 2.76M Dec/2025
MacroGenics USD -36.77M 22.62M Mar/2026
MannKind USD -16.62M 671K Mar/2026
Merck USD -1.34B 2.9B Jun/2026
Moderna USD -1.34B 517M Mar/2026
Novartis USD 3.26B 108M Jun/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Thermo Fisher Scientific USD 1.74B 85M Jun/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
United Therapeutics USD 333M 58.1M Jun/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024